This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

TearLab Corporation Reports Q2-10 Financial Results

SAN DIEGO, Aug. 12, 2010 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended June 30, 2010. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

For the three-months ended June 30, 2010, TearLab's net revenues were $418,134 as compared to $96,849 for the same period in 2009. The Company's loss for the second quarter of 2010 was approximately $1.5 million, or $0.10 per share, as compared to $1.0 million, or $0.10 per share, for the 2009 second quarter. 

For the six-months ended June 30, 2010, TearLab's net revenues were $693,129 as compared to $340,107 for the same period in 2009. The Company's loss for the first two quarters of 2010 was approximately $3.6 million, or $0.27 per share, as compared to $2.0 million, or $0.21 per share, for six months ended June 30, 2009. 

As of June 30, 2010, the Company had cash and cash equivalents and short-term investments of $4.8 million. Management believes that the Company has sufficient cash to cover its operating and other cash demands for at least the next 12 months.

"While our financial statements continue to reflect the very early stages of commercialization of the TearLab™ Osmolarity System in Europe and Canada, as demonstrated by our revenue growth this quarter, interest by clinicians in both markets has been building as evidence has continued to point to tear film osmolarity as the preferred tool in the evaluation of patients suffering from DED," commented Elias Vamvakas, TearLab's Chief Executive Officer.

Mr. Vamvakas continued, "We continue to endeavor to obtain the CLIA waiver categorization and approval for Medicare reimbursement as we believe that both of these milestones are key – not only to the widespread use and commercial success of the TearLab™ Osmolarity System in the U.S., but also to maximum penetration of the European and Canadian markets. As we wait for our full launch into the U.S., we continue to make strategic placements with key opinion leaders there."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs